Novartis launches the Cancer Cell Line Encyclopedia (CCLE) to catalogue world's cancer cell lines
(Thomson Reuters ONE) -
Novartis International AG /
Novartis launches the Cancer Cell Line Encyclopedia (CCLE) to catalogue world's
cancer cell lines
. Processed and transmitted by Thomson Reuters ONE.
The issuer is solely responsible for the content of this announcement.
* Collaboration with the Broad Institute yields comprehensive encyclopedia of
genetic and molecular information for nearly 1,000 cancer cell lines
* Encyclopedia, publicly available, may improve the design of cancer trials
and advance cancer research
* Data from encyclopedia may help researchers identify patients who could most
benefit from any given drug
Basel, March 28, 2012 - Novartis and the Broad Institute have developed a cancer
cell line encyclopedia that catalogues the genetic and molecular profiles of
almost 1,000 human cancer cell lines used in drug research and development.
Results of the collaboration, published in the journal Nature and released in
advance online today[1], may allow scientists around the world to use this
information to improve cancer clinical trial design and further cancer research.
"Cancer is a genetic disease. Cell lines reflect the genetic disturbances that
drive cancers. Probing cell lines with medicines targeted at specific pathways,
as done for the Cancer Cell Line Encyclopedia, provides a powerful tool for
design of cancer treatment," said Mark Fishman, President of the Novartis
Institutes for BioMedical Research (NIBR). "We are placing this information in
the public domain. We hope that many in industry and academia will use these
data to discover new drug targets, to evaluate current therapies, and to
facilitate treatment for their patients with cancer."
The genetic and molecular profiling data from the cell lines is freely available
to the scientific community here on the Broad Institute's website[2].
Investigators use cell lines to shed light on how new or existing cancer drugs
might best be used in patients. "Without access to a systematically collected
set of molecular data, researchers can't match experiments from cell lines with
patient tumors when new medicines become available," said William Sellers,
Global Head of Oncology, NIBR. "The Cancer Cell Line Encyclopedia will provide
scientists with the ability to build predictive models of what types of patients
will respond to a particular class of drugs."
The cell lines were acquired from commercial vendors in the U.S., Europe, Japan
and Korea and represent a diverse picture of cancer as a disease as they include
many subtypes of both common and rare forms of cancer. According to lead authors
and NIBR researchers Jordi Barretinaand Giordano Caponigro, each cell line was
genetically characterized through a series of high-throughput analyses at the
Broad Institute, including global RNA expression patterns, changes in DNA copy
number, as well as DNA sequence variations in about 1,600 genes associated with
cancer, and pharmacologic profiling for several drugs in about half of the cell
lines. Algorithms were developed to predict drug responses based on the genetic
and molecular makeup of cancer cells.
Pairing this information with ways to rapidly genotype patient tumor samples
represents the next step in the effort to enable the personalization of cancer
treatment. Some major research hospitals already routinely genetically profile
cancer patients' tumors, and many more are likely to follow, according to the
researchers.
Disclaimer
The foregoing release contains forward-looking statements that can be identified
by terminology such as "may," "could," "hope," "will," "predictive models," or
similar expressions, or by express or implied discussions regarding potential
new future products which may be developed with the assistance of the CCLE, or
regarding potential future revenues from such products. You should not place
undue reliance on these statements. Such forward-looking statements reflect the
current views of management regarding future events, and involve known and
unknown risks, uncertainties and other factors that may cause actual results to
be materially different from any future results, performance or achievements
expressed or implied by such statements. There can be no guarantee that any new
products will be developed or approved for marketing as a result of the CCLE.
Nor can there be any guarantee that any such products will achieve any
particular levels of revenue in the future. In particular, management's
expectations regarding CCLE could be affected by, among other things, unexpected
research results; unexpected clinical trial results, including unexpected new
clinical data and unexpected additional analysis of existing clinical data;
unexpected regulatory actions or delays or government regulation generally; the
impact that the foregoing factors could have on the values attributed to the
Novartis Group's assets and liabilities as recorded in the Group's consolidated
balance sheet, and other risks and factors referred to in Novartis AG's current
Form 20-F on file with the US Securities and Exchange Commission. Should one or
more of these risks or uncertainties materialize, or should underlying
assumptions prove incorrect, actual results may vary materially from those
anticipated, believed, estimated or expected. Novartis is providing the
information in this press release as of this date and does not undertake any
obligation to update any forward-looking statements contained in this press
release as a result of new information, future events or otherwise.
About Novartis
Novartis provides innovative healthcare solutions that address the evolving
needs of patients and societies. Headquartered in Basel, Switzerland, Novartis
offers a diversified portfolio to best meet these needs: innovative medicines,
eye care, cost-saving generic pharmaceuticals, preventive vaccines and
diagnostic tools, over-the-counter and animal health products. Novartis is the
only global company with leading positions in these areas. In 2011, the Group's
continuing operations achieved net sales of USD 58.6 billion, while
approximately USD 9.6 billion (USD 9.2 billion excluding impairment and
amortization charges) was invested in R&D throughout the Group. Novartis Group
companies employ approximately 124,000 full-time-equivalent associates and
operate in more than 140 countries around the world. For more information,
please visit http://www.novartis.com.
Novartis is on Twitter. Sign up to follow (at)Novartis at
http://twitter.com/novartis.
References
[1] Jordi Barretina and Giordano Caponigro, NIBR. The Cancer Cell Line
Encyclopedia enables predictive modeling of anticancer drug sensitivity.
[2] http://www.broadinstitute.org/ccle
# # #
Novartis Media Relations
Central media line :
+41 61 324 2200
Beth Calitri Mariellen Gallagher
Novartis Global Media Relations Novartis Institutes for BioMedical
+41 61 324 7973 (direct) Research
+41 79 523 0198 (mobile) +1 617 871 7665 (direct)
beth.calitri(at)novartis.com +1 617 909 9137 (mobile)
mariellen.gallagher(at)novartis.com
e-mail: media.relations(at)novartis.com
For Novartis multimedia content, please visit www.thenewsmarket.com/Novartis
For questions about the site or required registration, please contact:
journalisthelp(at)thenewsmarket.com.
Media release (PDF):
http://hugin.info/134323/R/1597980/503743.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Novartis International AG via Thomson Reuters ONE
[HUG#1597980]
Unternehmensinformation / Kurzprofil:
Datum: 28.03.2012 - 19:00 Uhr
Sprache: Deutsch
News-ID 129570
Anzahl Zeichen: 9057
contact information:
Town:
Basel
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 215 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Novartis launches the Cancer Cell Line Encyclopedia (CCLE) to catalogue world's cancer cell lines"
steht unter der journalistisch-redaktionellen Verantwortung von
Novartis International AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
